经内镜逆行性胰胆管造影术后并发症相关影响因素分析及防治进展

doi:10.3969/j.issn.1004-583X.2023.06.013

摘要/Abstract

摘要：

经内镜逆行性胰胆管造影(endoscopic retrograde cholangiopancreatography,ERCP)是诊治胆、胰系统疾病的常用方法之一。但它可引起胰腺炎、穿孔、出血及感染等并发症,本文就近年来有关ERCP并发症发生的危险因素及其防治的文献进行综述。

关键词: 胰胆管造影术, 内窥镜逆行, 并发症, 胰腺炎, 出血, 穿孔

中图分类号:

R816.5

高福生, 张川, 展玉涛. 经内镜逆行性胰胆管造影术后并发症相关影响因素分析及防治进展[J]. 临床荟萃, 2023, 38(6): 550-553.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2023.06.013

https://huicui.hebmu.edu.cn/CN/Y2023/V38/I6/550

参考文献 39

[1]	中华医学会消化内镜学分会ERCP学组, 中国医师协会消化医师分会胆胰学组, 国家消化系统疾病临床医学研究中心. 中国ERCP指南(2018版)[J]. 中华消化内镜杂志, 2018, 35(11):777-813.
[2]	Dumonceau JM, Kapral C, Aabakken L, et al. ERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) Guideline[J]. Endoscopy, 2020, 52(2):127-149. doi: 10.1055/a-1075-4080 URL
[3]	Tryliskyy Y, Bryce GJ. Post-ERCP pancreatitis: Pathophysiology, early identification and risk stratification[J]. Adv Clin Exp Med. 2018, 27(1):149-154. doi: 10.17219/acem/66773 pmid: 29521055
[4]	Han S, Attwell AR, Tatman P, et al. Adverse events associated with therapeutic endoscopic retrograde pancreatography[J]. Pancreas, 2021, 50(3):378-385. doi: 10.1097/MPA.0000000000001769 URL
[5]	Kato K, Shiba M, Kakiya Y, et al. Celecoxib oral administration for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis a randomized prospective trial[J]. Pancreas, 2017, 46(7):880-886. doi: 10.1097/MPA.0000000000000852 URL
[6]	Jang DK, Kim J, Paik CN, et al. Endoscopic retrograde cholangiopancreatography‐related adverse events in Korea: A nationwide assessment[J]. United European Gastroenterol J, 2022, 10(1): 73-79. doi: 10.1002/ueg2.v10.1 URL
[7]	Zhao ZH, Hu LH, Ren HB, et al. Incidence and risk factors for post-ERCP pancreatitis in chronic pancreatitis[J]. Gastrointest Endosc, 2017, 86(3): 519-524.e511. doi: 10.1016/j.gie.2016.12.020 URL
[8]	Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy[J]. N Engl J Med, 1996, 335(13): 909-919. doi: 10.1056/NEJM199609263351301 URL
[9]	Sundaralingam P, Masson P, Bourke MJ. Early precut sphincterotomy does not increase risk during endoscopic retrograde cholangiopancreatography in patients with difficult biliary access: A meta-analysis of randomized controlled trials[J]. Clin Gastroenterol Hepatol, 2015, 13(10):1722-1729. doi: 10.1016/j.cgh.2015.06.035 URL
[10]	Fujita K, Yazumi S, Matsumoto H, et al. Multicenter prospective cohort study of adverse events associated with biliary endoscopic retrograde cholangiopancreatography: Incidence of adverse events and preventive measures for post-endoscopic retrograde cholangiopancreatography pancreatitis[J]. Dig Endosc, 2022, 34(6):1198-1204. doi: 10.1111/den.v34.6 URL
[11]	Cha SW, Leung WD, Lehman GA, et al. Does leaving a main pancreatic duct stent in place reduce the incidence of precut biliary sphincterotomy-associated pancreatitis? A randomized, prospective study[J]. Gastrointest Endosc, 2013, 77(2):209-216. doi: 10.1016/j.gie.2012.08.022 URL
[12]	Akshintala VS, Sperna Weiland CJ, Bhullar FA, et al. Non-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and network meta-analysis[J]. Lancet Gastroenterol Hepatol, 2021, 6(9):733-742. doi: 10.1016/S2468-1253(21)00170-9 URL
[13]	Sotoudehmanesh R, Ali-Asgari A, Khatibian M, et al. Pharmacological prophylaxis versus pancreatic duct stenting plus pharmacological prophylaxis for prevention of post-ERCP pancreatitis in high risk patients: a randomized trial[J]. Endoscopy, 2019, 51(10): 915-921. doi: 10.1055/a-0977-3119 pmid: 31454851
[14]	Chandrasekhara V, Khashab MA, Muthusamy VR, et al. Adverse events associated with ERCP[J]. Gastrointest Endosc, 2017, 85(10): 32-47. doi: 10.1016/j.gie.2016.06.051 URL
[15]	Choi JH, Kim HJ, Lee BU, et al. Vigorous periprocedural hydration with lactated ringer’s solution reduces the risk of pancreatitis after retrograde cholangiopancreatography in hospitalized patients[J]. Clin Gastroenterol Hepatol, 2017, 15(1): 86-92.e1. doi: 10.1016/j.cgh.2016.06.007 URL
[16]	Elmunzer BJ, Scheiman JM, Lehman GA, et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis[J]. N Engl J Med, 2012, 366(15): 1414-1422. doi: 10.1056/NEJMoa1111103 URL
[17]	Kubiliun NM, Adams MA, Akshintala VS, et al. Evaluation of pharmacologic prevention of pancreatitis after endoscopic retrograde cholangiopancreatography: A systematic review[J]. Clin Gastroenterol Hepatol, 2015, 13(7): 1231-1239. doi: 10.1016/j.cgh.2014.11.038 URL
[18]	Luo H, Zhao L, Leung J, et al. Routine pre-procedural rectal indometacin versus selective post-procedural rectal indometacin to prevent pancreatitis in patients undergoing endoscopic retrograde cholangiopancreatography: a multicentre, single-blinded, randomised controlled trial[J]. Lancet, 2016, 387(10035): 2293-2301. doi: S0140-6736(16)30310-5 pmid: 27133971
[19]	Thiruvengadam NR, Forde KA, Ma GK, et al. Rectal indomethacin reduces pancreatitis in high-and low-risk patients undergoing endoscopic retrograde cholangiopancreatography[J]. Gastroenterology, 2016, 151(2): 288-297.e284. doi: 10.1053/j.gastro.2016.04.048 pmid: 27215656
[20]	Dumonceau JM, Andriulli A, Elmunzer BJ, et al. Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) guideline-updated June 2014[J]. Endoscopy, 2014, 46(9): 799-815. doi: 10.1055/s-00000012 URL
[21]	Lyu Y, Wang B, Cheng Y, et al. Comparative efficacy of 9 major drugs for postendoscopic retrograde cholangiopancreatography pancreatitis: A network meta-analysis[J]. Surg Laparosc Endosc Percutan Tech, 2019, 29(6):426-432. doi: 10.1097/SLE.0000000000000707 pmid: 31490455
[22]	Thiruvengadam NR, Forde KA, Chandrasekhara V, et al. Tacrolimus and indomethacin are safe and effective at reducing pancreatitis after endoscopic retrograde cholangiopancreatography in patients who have undergone liver transplantation[J]. Clin Gastroenterol Hepatol, 2020, 18(5):1224-1232.e1. doi: 10.1016/j.cgh.2019.10.014 URL
[23]	Wang G, Xiao G, Xu L, et al. Effect of somatostatin on prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis and hyperamylasemia: A systematic review and meta-analysis[J]. Pancreatology, 2018, 18(4): 370-378. doi: S1424-3903(18)30040-1 pmid: 29550097
[24]	Prachayakul V, Aswakul P. Endoscopic retrograde cholangiopancreatography-related perforation: management and prevention[J]. World J Clin Cases, 2014, 2(10):522-527. doi: 10.12998/wjcc.v2.i10.522 pmid: 25325062
[25]	Artifon EL, Minata MK, Cunha MA, et al. Surgical or endoscopic management for post-ERCP large transmural duodenal perforations: A randomized prospective trial[J]. Rev Gastroenterol Peru, 2015, 35(4):313 -317. pmid: 26802884
[26]	Weiser R, Pencovich N, Mlynarsky L, et al. Management of endoscopic retrograde cholangiopancreatography-related perforations: Experience of a tertiary center[J]. Surgery, 2017, 161(4):920-929. doi: 10.1016/j.surg.2016.10.029 URL
[27]	Cotton PB, Garrow DA, Gallagher J, et al. Risk factors for complications after ERCP: a multivariate analysis of 11, 497 procedures over 12 years[J]. Gastrointest Endosc, 2009, 70(1):80-88. doi: 10.1016/j.gie.2008.10.039 pmid: 19286178
[28]	Jin YJ, Jeong S, Kim JH, et al. Clinical course and proposed treatment strategy for ERCP-related duodenal perforation: a multicenter analysis[J]. Endoscopy, 2013; 45(10):806 -812. doi: 10.1055/s-00000012 URL
[29]	Patil NS, Solanki N, Mishra PK, et al. ERCP-related perforation: an analysis of operative outcomes in a large series over 12 years[J]. Surg Endosc, 2020, 34(1):77 -87. doi: 10.1007/s00464-019-06733-x
[30]	Niu F, Liu YD, Chen RX, et al. Safety and efficacy of enhanced recovery after surgery in elderly patients after therapeutic endoscopic retrograde cholangiopancreatography[J]. Wideochir Inne Tech Maloinwazyjne, 2019, 14(3):394-400.
[31]	Theopistos V, Theocharis G, Konstantakis C, et al. Non-operative management of type 2 ERCP-related retroperitoneal duodenal perforations: A 9-year experience from a single center[J]. Gastroenterology Res, 2018, 11(3):207 -212. doi: 10.14740/gr1007w URL
[32]	Park TY, Bang CS, Choi SH, et al. Forward-viewing endoscope for ERCP in patients with Billroth II gastrectomy: A systematic review and meta-analysis[J]. Surg Endosc, 2018, 32(11):4598 -4613. doi: 10.1007/s00464-018-6213-1 pmid: 29777352
[33]	Inamdar S, Berzin TM, Berkowitz J, et al. Decompensated cirrhosis may be a risk factor for adverse events in endoscopic retrograde cholangiopancreatography[J]. Liver Int, 2016, 36(10):1457 -1463. doi: 10.1111/liv.13100 pmid: 26913829
[34]	Kim JY, Lee HS, Chung MJ, et al. Bleeding complications and clinical safety of endoscopic retrograde cholangiopancreatography in patients with liver cirrhosis[J]. Yonsei Med J, 2019, 60(5):440 -445. doi: 10.3349/ymj.2019.60.5.440 pmid: 31016905
[35]	Johnson KD, Perisetti A, Tharian B, et al. Endoscopic retrograde cholangiopancreatography-related complications and their management strategies: A “Scoping” Literature Review[J]. Dig Dis Sci, 2020, 65(2):361 -375. doi: 10.1007/s10620-019-05970-3
[36]	Li J, Li T, Sun P, et al. Covered versus uncovered self-expandable metal stents for managing malignant distal biliary obstruction: A meta-analysis[J]. PLoS One, 2016, 11(2):e0149066. doi: 10.1371/journal.pone.0149066 URL
[37]	Chen M, Wang L, Wang Y, et al. Risk factor analysis of post-ERCP cholangitis: A single-center experience[J]. Hepatobiliary Pancreat Dis Int, 2018, 17(1):55-58. doi: 10.1016/j.hbpd.2018.01.002 URL
[38]	Du M, Suo J, Liu B, et al. Post-ERCP infection and its epidemiological and clinical characteristics in a large Chinese tertiary hospital: A 4-year surveillance study[J]. Antimicrob Resist Infect Control, 2017, 29(6):131 -136.
[39]	Wobser H, Gunesch A, Klebl F. Prophylaxis of post-ERC infectious complications in patients with biliary obstruction by adding antimicrobial agents into ERC contrast media-a single center retrospective study[J]. BMC Gastroenterol, 2017, 17(1): 1-8. doi: 10.1186/s12876-016-0563-8 URL

经内镜逆行性胰胆管造影术后并发症相关影响因素分析及防治进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 39

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘岩, 刘琼, 梁晓梅, 刘冰. 以发热为主要症状的自发性肾出血继发感染1例并文献复习[J]. 临床荟萃, 2023, 38(9): 823-826.
[2]	陈聪水, 李园, 陈淑芳. 重视儿童胆源性胰腺炎的中西医诊治(附1例分析)[J]. 临床荟萃, 2023, 38(8): 726-730.
[3]	马光宇, 罗慧娟, 王冬菊, 肖小敏. 黄芩苷治疗糖尿病及其并发症的研究进展[J]. 临床荟萃, 2023, 38(8): 757-762.
[4]	刘倩, 马士恒, 张旭. 流行性腮腺炎并发急性肾衰竭1例及文献复习[J]. 临床荟萃, 2023, 38(6): 541-543.
[5]	于雪华, 张宁, 吴婧, 孙惠, 赵云红, 刘改芳. 血清抵抗素、丙二醛、IL-6联合检测对急性胰腺炎严重程度的预测价值[J]. 临床荟萃, 2023, 38(5): 412-416.
[6]	辛在娥. 误诊为脑膜炎的蛛网膜下腔出血1例及文献复习[J]. 临床荟萃, 2023, 38(5): 448-450.
[7]	马明福, 魏志国, 何铁英. 急性胰腺炎并发胰腺假性囊肿危险因素的meta分析[J]. 临床荟萃, 2023, 38(4): 293-301.
[8]	翟华珍, 李凌翔, 林秋满, 赖颖瑜, 杨心怡, 邓敏. 重症急性胰腺炎治疗及营养支持的研究进展[J]. 临床荟萃, 2023, 38(12): 1135-1139.
[9]	任道聪, 王宁, 孟庆顺. 中西医结合治疗重症急性胰腺炎[J]. 临床荟萃, 2023, 38(10): 931-934.
[10]	邢婷婷, 高俊茶. Presepsin在急性胰腺炎中的研究进展[J]. 临床荟萃, 2022, 37(8): 764-768.
[11]	郭卫娜, 康宁, 李晓莎, 李玲, 高俊淑, 李娜, 王天俊. 急性胰腺炎致Wernicke-Korsakoff综合征伴乳头体萎缩1例[J]. 临床荟萃, 2022, 37(7): 644-647.
[12]	李文哲, 商进春, 李春梅, 田芬, 李君, 崔莉, 邢广群. 尿毒症规律血液透析患者脑出血危险因素分析[J]. 临床荟萃, 2022, 37(1): 20-25.
[13]	史晓英, 何洪真, 郭星, 吕佩源. 脑白质高信号与自发性脑出血[J]. 临床荟萃, 2021, 36(6): 562-565.
[14]	吴昊, 李静. RDW、NLR、D-二聚体联合检测对急性胰腺炎病情的预测价值[J]. 临床荟萃, 2021, 36(6): 504-508.
[15]	李文哲, 商进春, 李春梅, 李君, 田芬, 崔莉, 陈怿鹏, 张小凡, 邢广群. 枸橼酸钠抗凝连续性肾脏替代治疗救治尿毒症脑出血患者的优势[J]. 临床荟萃, 2021, 36(5): 425-431.